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Background-—Depression has been related to mortality in coronary heart disease (CHD) patients, but few studies have evaluated
the role of anxiety or the role of the co-occurrence of depression and anxiety. We examined whether anxiety is associated with
increased risk of mortality after accounting for depression in individuals with established CHD.
Methods and Results-—The cohort was composed of 934 men and women with confirmed CHD (mean age, 6211 years) who
completed the Hospital Anxiety and Depression scale (HADS) during hospitalization for coronary angiography. Over the 3-year
follow-up period, there were 133 deaths. Elevated scores on the HADS anxiety subscale (HADS-A≥8) were associated with
increased risk of mortality after accounting for established risk factors including age, congestive heart failure, left ventricular
ejection fraction, 3-vessel disease, and renal disease (hazard ratio [HR], 2.27; 95% CI, 1.55 to 3.33; P<0.001). Elevated scores on
the HADS depression subscale (HADS-D≥8) were also associated with increased risk of mortality (HR, 2.18; 95% CI, 1.47 to 3.22;
P<0.001). When both psychosocial factors were included in the model, each maintained an association with mortality (anxiety, HR,
1.83; 95% CI, 1.18 to 2.83; P=0.006; depression, HR, 1.66; 95% CI, 1.06 to 2.58; P=0.025). Estimation of the HR for patients with
both anxiety and depression versus those with neither revealed a larger HR than for patients with either factor alone (HR, 3.10; 95%
CI, 1.95 to 4.94; P<0.001).
Conclusions-—Anxiety is associated with increased risk of mortality in CHD patients, particularly when comorbid with depression.
Future studies should focus on the co-occurrence of these psychosocial factors as markers of increased mortality risk. ( J Am
Heart Assoc. 2013;2:e000068 doi: 10.1161/JAHA.112.000068)
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O ver the last 2 decades, a number of prospectiveepidemiological studies have provided support for an
association of depression with mortality in coronary heart
disease (CHD) patients.1–3 However, relatively little attention
has focused on the role played by anxiety in depression-
related risk, despite the extensive comorbidity shared
between depression and anxiety.4–6 Chronic anxiety is
accompanied by a number of pathophysiological processes
including elevated sympathetic nervous system activity,7–9
inflammation,10–13 and hypertension.14 Anxiety has also been
associated with increased risk of cardiac mortality in prospec-
tive cohort studies of medically healthy individuals15–19
and in a number of CHD patient populations.20–27 However,
not all studies have found an association between anxiety and
poor clinical outcomes in CHD patients.28–31
The goal of the present study was to evaluate the
explanatory roles of anxiety alone and of comorbid anxiety
and depression for mortality risk in patients with established
CHD. Anxiety and depression were assessed using the
Hospital Anxiety and Depression scale (HADS), a scale
developed specifically to discriminate anxiety from depression
in medically ill hospitalized patients.32
Methods
Participants
VAGUS (Very Anxious Group Under Scrutiny) was a prospec-
tive study designed to evaluate the relationship of anxiety
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with risk of adverse clinical outcomes in CHD patients. All
patients were enrolled at Duke University Medical Center over
a 27-month period during an inpatient or outpatient visit for
diagnostic cardiac catheterization. To be eligible for the study,
patients were required to have either cardiac catheterization–
confirmed significant stenosis (≥75%) of >1 major coronary
artery or a documented history of prior myocardial infarction
(MI) or revascularization procedure. Of the 9162 patients
undergoing left heart cardiac catheterization during the
enrollment period, 8028 charts were available for screening,
and approximately one-third of these patients (n=2549) were
excluded because of insignificant CAD. Because one aspect of
the parent study focused on heart rate variability (HRV),
approximately one-third of the available patients (n=2894)
were excluded because they were not in normal sinus rhythm
or had a 30-day history of myocardial infarction and/or
revascularization. Eight percent (n=627) were not approached
because of medical, physical, or psychiatric complications
that could impact the patient’s ability to communicate (eg,
ventilator dependence, stroke-related aphasia, language con-
flict, psychosis). Of the 955 patients enrolled in the VAGUS
study, 21 patients were unable to complete the HADS, leaving
a study sample of 934 (see Figure 1). Of these 21 patients, 6
died and 15 survived. The 21 patients with missing HADS data
were comparable to the others in terms of all other
demographics and medical history variables, suggesting that
completion of the HADS is unlikely to have affected the study
findings. This study was approved by the Duke University
Medical Center Institutional Review Board, and all patients
gave written informed consent before participating in the
research protocol.
Measures of Medical Disease Severity and
Lifestyle Factors
Medical history, current diagnoses, medications, blood
pressure, and coronary disease treatment plan (medical/
revascularization/surgical) were extracted from patient
hospital charts. A modified version of the Stanford 7-day
physical activity recall interview33 was used to estimate
physical activity and habitual sleep duration during the
7-day period prior to hospitalization. Left ventricular ejec-
tion fraction (LVEF) and degree of coronary artery stenosis
were obtained from the cardiac catheterization report.
Education status and smoking status were obtained through
patient interview.
Assessment of Anxiety and Depression
The Hospital Anxiety and Depression Scale (HADS) is a 14-
item self-report questionnaire comprising 4-point Likert-
scaled items covering the occurrence of symptoms of anxiety
(HADS-A) and depression (HADS-D) over the past 2 weeks.32
The HADS was specifically designed to avoid false-positives
when administered in hospital settings and therefore focuses
on psychological and cognitive symptoms, rather than
somatic symptoms or sleep and appetite disturbance. The
majority of the symptoms included in the HADS-A are indices
of generalized anxiety, with only 1 item related to panic. The
depression scale primarily comprises symptoms of anhedonia.
Internal consistency (Cronbach’s alpha) for the HADS-A and
HADS-D ranged from 0.67 to 0.93 in previous studies34 and
was 0.78 for each subscale in the current sample. A 2-factor
structure of the HADS has been confirmed in a number of
studies,35–37 and a cutoff score of 8 on the HADS-A subscale
(range, 0 to 21) and 8 on the HADS-D subscale (range, 0 to
21) has been found to provide the optimal balance between
sensitivity and specificity for identifying cases,34 as originally
recommended by Zigmond and Snaith.32 Results from 1
recent study indicated that approximately 21% of community-
dwelling individuals score ≥8 on the HADS-A subscale and
23% score ≥8 on the HADS-D scale.38 The HADS has
moderate test-retest reliability (r>0.8), and average sensitiv-
ities and specificities of ≥0.8.39–41 Among the 934 patients
included, 928 had no missing items, and 6 had only 1 missing
item, which was replaced using the mean score of the other
items on the subscale in question.
End-Point Ascertainment
All patients were contacted by mail at 6 months and annually
thereafter up to 4 years after the initial assessment to
document hospitalizations and vital status. For patients who







Recent MI or revasculariza on (n=2158)
Comorbidity/complica ons (n=627)
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HADS not completed: n=21
Figure 1. Flow chart showing numbers of patients screened,
excluded, and enrolled. CAD indicates coronary artery disease; MI,
myocardial infarction; HADS, Hospital Anxiety and Depression Scale.
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notes, and supporting documentation (EKG and laboratory
results) were obtained for each cardiac-related rehospitaliza-
tion during the follow-up period. If medical records were
inconclusive or not available, a telephone interview with the
next of kin was used to ascertain or confirm the circum-
stances leading to death. An end-point committee consisting
of 2 cardiologists (M.H.S. and C.O.) blinded to HADS anxiety
and depression scores reviewed medical records and tele-
phone interviews to determine cause of death. A consensus
was reached for each case. All 934 patients were included in
the mortality analyses, with 22 lost during the follow-up
period. Among these 22, 2 were lost within the first month,
and the other 20 withdrew consent or were lost to follow-up
after a mean of 1.20.7 years from the time of their baseline
assessment. The 22 patients with missing follow-up data were
comparable to the others in all other demographics and
medical history variables, including scores on the HADS
anxiety scale (complete follow-up, 4.44.0; partial follow-up,
4.84.8) and the HADS depression scale (complete follow-up,
4.34.1; partial follow-up, 3.34.1).
Analytic Methods
Cox proportional hazards models were used to examine the
association between baseline characteristics and mortality
during a median follow-up period of 3 years. The primary end
point was time until death. Anxiety and depression were
identified using the cutoff scores shown to have optimal
sensitivity and specificity for detecting anxiety disorders and
clinical depression (anxiety cases, HADS-A scores ≥8; depres-
sion cases, HADS -D scores ≥8).32 In the originally planned
model, age, congestive heart failure (CHF), presence of 3-vessel
coronary artery disease, LVEF, and renal disease were evalu-
ated with anxiety and/or depression, both separately and
together. None of the explanatory variables in the planned
model had any missing data. In addition to evaluating the
association with all-cause mortality, analyses were repeated to
evaluate the association between anxiety and depression and
cardiovascular mortality, the most common cause of death.
These analyses included all observations and treated the
noncardiovascular deaths as censored observations.
To determine the robustness of the planned model,
analyses considered other potentially relevant factors (sex,
diabetes, internal cardioverter defibrillator [ICD], coronary
artery bypass graft [CABG] treatment, smoking, diuretic use,
insulin use, antidepressant use, benzodiazepine use, educa-
tion status, and hypertension history), which were made
available for possible entry into the model by stepwise
selection (significance level required for entry into the model:
P≤0.10). The only role of these extended analyses was to
examine whether other factors modified the interpretation of
anxiety and depression as explanatory because the analysis
was not intended to develop a predictive model for patient
outcome. For this expanded model, none of the variables had
any missing data except for education, which was only
missing 4 observations, and these missing variables had no
influence on the findings. We repeated the analyses evaluat-
ing HADS-A and HADS-D scores as continuous variables, with
scores on the HADS-A or HADS-D scale divided by 5 in order
to produce more meaningful units of description for hazard
ratios. In addition, we evaluated risk across quartiles of HADS-A
and HADS-D scores to examine whether each was related to
mortality risk in a graded fashion. We also evaluated how
anxiety and depression work together to predict mortality risk
by fitting models that included their interaction. These models
not only enabled evaluation of the interaction but also
provided hazard ratios for anxiety only contrasted both with
patients with neither anxiety nor depression and patients with
depression only. Similarly, these models provided hazard
ratios for depression only contrasted both with patients with
neither anxiety nor depression and patients with anxiety only.
These models also enabled the evaluation of the hazard ratio
for comorbid anxiety and depression versus the absence of
both.
Results
The patient sample was 70% male and 79% white, with a mean
age of 62 years (range, 29 to 90 years; see Table 1). Scores
ranged from 0 to 19 on the HADS-A subscale and from 0 to
21 on the HADS-D subscale. Approximately 20% of the sample
reported HADS-A or HADS-D scores at or above the cutoff of
8 recommended for identifying clinically significant anxiety
and depression. HADS-A and HADS-D scores were signifi-
cantly correlated (r=0.66, P<0.001), and 60% of the cases
classified as depressed also met criteria for elevated anxiety,
and 52% of the anxiety cohort met criteria for elevated
depression. When evaluated in the full cohort, both HADS-A
and HADS-D scores were associated with younger age
(anxiety: r=0.25, P<0.001; depression: r=0.18, P<0.001)
and higher rates of smoking (anxiety: r=0.13, P<0.001;
depression: r=0.15, P<0.001). However, only the HADS
anxiety scores were associated with reduced sleep duration
(r=0.09, P=0.016), female sex (r=0.07, P=0.032), greater
body mass index (r=0.07, P=0.027), and hypertension history
(r=0.06, P=0.056). Similarly, only the HADS depression scores
were associated with congestive heart failure (r=0.13,
P<0.001) and lower LVEF (r=0.07, P=0.037). When groups
with anxiety only and depression only were contrasted with
patients without elevated symptoms of anxiety or depression
(see Table 1), anxiety’s association with reduced sleep
duration and female sex were retained, but anxiety was no
longer associated with smoking and was associated with
lower alcohol consumption (see Table 1).
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Table 1. Demographic and Clinical Characteristics of Study Groups
Neither (n=680) Anxiety† Only (n=90) Depression‡ Only (n=65) Anxiety† and Depression‡ (n=99)
Demographics
Female, % 29 43** 26 32
Age, y 6311 6010 6211 5511***
Minority, % 21 18 11 29
Obese, % 39 48 49 43
BMI, kg/m2 29.55.9 31.37.8** 31.59.0* 29.67.3
<HS education, % 31 36 31 34
Daily sleep, h 7.22.0 6.62.1* 7.13.5 6.82.7
Alcohol consumption,%
Never 58 74* 62 65
Lowk 24 18 23 25
Moderate-High¶ 18 8* 15 10
Risk factors and medical history
Current smokers, % 12 11 22 32***
HTN history, % 78 86 85 80
SBP 13017 13117 12817 12518**
DBP 6910 7011 6912 6711
Diabetes history, % 36 43 37 42
MI history, % 42 37 49 51
3-Vessel CAD, % 46 43 37 30***
CABG treatment, % 29 31 25 28
LVEF≤40%, % 16 18 26 26**
CHF, % 18 24 35† 29**
ICD, % 2 7** 6 6
PVD, % 24 27 20 27
CVD, % 16 17 25 15
COPD, % 15 19 23 17
PUD, % 11 10 5 8
Renal disease, % 15 10 11 13
Prognostic medications, %
Benzodiazepines 9 18** 18 19**
Antidepressants 18 21 34** 30**
Insulin 15 21 18 25**
Diuretics 34 41 52** 37
Psychosocial assessments
HADS anxiety score 32 102*** 42*** 123***
HADS depression score 22 52*** 102*** 134***
All-cause mortality,% 11.5 17 18.5 29***
High rehospitalization rate§, % 17 26 17 33***
Contrasts are with patients with HADS-A and HADS-D scores <8; sleep duration available only in a subset of 791 patients; alcohol use available only in a subset of 807 patients.
BMI indicates body mass index; HS, high school; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; CAD, coronary artery disease;
CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; CHF, congestive heart failure; ICD, implantable cardioverter defibrillator; PVD, peripheral vascular disease;






§>1 Rehospitalization per year during follow-up.
k<2 Drinks per month.
¶Daily alcohol consumption.
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Association of Anxiety and Depression With
All-Cause Mortality
Over the 3-year follow-up period, there were 133 deaths.
Twenty-two deaths were adjudicated to be related to a
medical procedure occurring during hospitalization at baseline
or hospitalization during the follow-up period. Of these 22
deaths, 5 met criteria for elevated anxiety, and 7 met criteria
for elevated depression.
Elevated anxiety or depression symptoms, defined using
the predetermined cutoff points of 8, recommended by
Zigmond and Snaith to identify clinical cases of anxiety and
depression,32 were separately associated with mortality after
adjusting for variables in the original planned model, which
included age, CHF, 3-vessel coronary artery disease, LVEF, and
renal disease (elevated anxiety HR, 2.27; 95% CI, 1.55 to 3.33;
P<0.001; elevated depression HR, 2.18; 95% CI, 1.47 to 3.22;
P<0.001). Although dichotomization at 8 has been found to
have the highest sensitivity and specificity to identify anxiety
disorders and depression in primary care patients and noncan-
cer medical patients, a cutoff of 9 on the HADS-A subscale has
been found to be optimal to identify anxiety disorders in some
patient populations such as cancer patients (whereas a cutoff
point of 8 on the HADS-D subscale remained optimal for
depression in this population).34 When HADS-A scores were
dichotomized at 9, anxiety continued to be associated with
mortality (HR, 2.63; 95% CI, 1.73 to 3.99; P<0.001).
The opportunity provided by stepwise selection of all other
baseline characteristics extended the planned model by also
including ICD, antidepressant use, and insulin use. No other
variables were selected for the model through stepwise
selection. In this extended model, anxiety scores of ≥8
continued to be associated with a 2-fold increased risk of
mortality (HR, 2.00; 95% CI, 1.35 to 2.97; P<0.001), and similar
findings were observed with depression (HR, 1.69; 95% CI, 1.13
to 2.54; P=0.011). These results support the robustness of the
findings for anxiety and depression from the planned model.
Anxiety and All-Cause Mortality in the Context
of Comorbid Depression
Including both depression and anxiety status in the planned
model did not eliminate the association between anxiety and
mortality (HR, 1.83; 95% CI, 1.18 to 2.83 P=0.006) or the
association between depression and mortality (HR, 1.66; 95%
CI, 1.06 to 2.58; P=0.025; see Table 2). However, in the
model extended by stepwise selection and containing both
depression and anxiety, anxiety continued to be associated
with mortality (HR, 1.79; 95% CI, 1.15 to 2.78; P=0.010), but
the association of depression with mortality was attenuated
(HR, 1.31; 95% CI, 0.82 to 2.05; P=0.27).
For both the planned and the extended models, evaluation
of an interaction term for anxiety and depression showed that
it was not explanatory (planned model, P=0.70; extended
model, P=0.66). Nevertheless, inclusion of the interaction
term for anxiety and depression is of interest for showing the
similarity of the association between anxiety and mortality
when contrasted with patients with neither anxiety nor
depression (planned model HR, 1.71; 95% CI, 0.98 to 3.00;
P=0.060) and when contrasted with patients with depression
only (planned model HR, 2.04; 95% CI, 1.00 to 4.17; P=0.049;
see Table 3). Similarly, inclusion of the interaction term
showed the similarity of the association between depression
and mortality when contrasted with patients with neither
anxiety nor depression (planned model HR, 1.52; 95% CI, 0.80 to
Table 2. Cox Proportional Regression Analyses for All-Cause Mortality
Variable Planned Model* HR (95% CI) P Value Extended Model† HR (95% CI) P Value
Anxiety 1.83 (1.18 to 2.83) 0.006 1.79 (1.15 to 2.78) 0.010
Depression 1.66 (1.06 to 2.58) 0.025 1.31 (0.82 to 2.05) 0.27
Age tertile 1.66 (1.32 to 2.09) <0.001 1.83 (1.45 to 2.32) <0.001
CHF 2.44 (1.62 to 3.68) <0.001 2.15 (1.42 to 3.28) <0.001
3-Vessel CAD 1.78 (1.24 to 2.54) 0.002 1.85 (1.29 to 2.65) <0.001
LVEF 0.99 (0.97 to 1.00) 0.063 0.99 (0.97 to 1.00) 0.065
Renal disease 2.22 (1.51 to 3.27) <0.001 2.19 (1.46 to 3.28) <0.001
ICD — 5.49 (3.23 to 9.33) <0.001
Antidepressant use — 1.90 (1.29 to 2.80) 0.001
Insulin 1.59 (1.06 to 2.38) 0.025
HR indicates hazard ratio; CI, confidence interval; CHF, congestive heart failure; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter
defibrillator.
*Adjusted for age tertile, CHF, presence of 3-vessel disease, left ventricular ejection fraction, and renal disease (end-stage renal disease and chronic renal insufficiency).
†Adjusted for the variables in the a priori planned model, as well as presence of an internal cardioverter defibrillator, antidepressant use, and insulin use.
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2.88; P=0.20) and when contrasted with patients with anxiety
only (planned model HR, 1.81; 95% CI, 0.96 to 3.43; P=0.070).
Moreover, this model showed a 3-fold increased risk of
mortality for patients with comorbid anxiety and depression
versus those with neither (planned HR, 3.10; 95% CI, 1.95 to
4.94; P<0.001), with this increased risk being comparable to
that produced by the product of the separate hazard ratios for
anxiety and depression in the planned model without the
interaction term for anxiety and depression (HR=1.839
1.66=3.04; 95% CI, 1.93 to 4.79; P<0.001).
Graded Association of Anxiety and Depression
An association with all-cause mortality was also observed
when either anxiety or depression was represented in the
planned model using continuous scores on the HADS anxiety
subscale (HADS anxiety score/5 HR, 1.59; 95% CI, 1.30 to
1.96; P<0.001) or continuous scores on the HADS depression
subscale (HADS depression score/5 HR, 1.54; 95% CI, 1.29 to
1.85; P<0.001). Including both anxiety and depression
scores/5 in the same model resulted in some attenuation
of the association between anxiety and mortality (HR, 1.29;
95% CI, 0.98 to 1.70; P=0.069) but not between depression
and mortality (HR, 1.33; 95% CI, 1.04 to 1.70; P=0.024).
Evaluation of an interaction term for anxiety and depression
showed that it was not explanatory (P=0.97). As shown
descriptively using survival curves, an association with all-
cause mortality was observed for quartiles of anxiety and
depression in the setting of no adjustment for baseline
characteristics (see Figures 2 and 3). A graded increase in
mortality was observed with increasing quartile of HADS-D
score. In contrast, the association between anxiety and risk
appeared to be driven largely by the fourth quartile of scores,
which corresponds to participants with anxiety values of ≥8.
Association of Anxiety and Depression With
Cardiovascular Mortality
The majority of deaths in the current cohort were attributed to
cardiovascular causes (93 of the 133). Elevated anxiety and
depression (HADS scores ≥8) showed similar associations with
cardiovascular deaths as observed with all-cause mortality when
evaluated separately (anxiety HR, 2.11; 95% CI, 1.33 to 3.35;
P=0.002; depressionHR, 2.02; 95%CI, 1.26 to 3.24; P=0.004) and
when included in the samemodel together (anxiety HR, 1.75; 95%
CI, 1.04 to 2.94; P=0.036; depression HR, 1.58; 95% CI, 0.93 to
2.69; P=0.093). There were no significant interactions between
anxiety and depression in these models.
Discussion
Anxiety is common in Western societies, with approximately
30% of US adults reporting a clinically significant anxiety
disorder during their lifetimes.42 In the current cohort of CHD
patients, those with elevated anxiety symptoms showed a
2-fold increased risk of mortality, suggesting that anxiety has
Table 3. Hazard Ratios and 95% Confidence Intervals for All-Cause Mortality
Neither Anxiety nor Depression (n=680) Anxiety Only (n=90) Depression Only (n=65) Anxiety and Depression (n=99)
Number of deaths 78 15 12 28
Planned Model HR*
Versus neither 1.00 (ref) 1.71 (0.98 to 3.00) 1.52 (0.80 to 2.88) 3.10 (1.95 to 4.94)
Versus anxiety alone NA 1.00 (ref) NA 1.81 (0.96 to 3.43)
Versus depression alone NA NA 1.00 (ref) 2.04 (1.00 to 4.17)
HR indicates hazard ratio; CI, confidence interval; ref, reference; CHF, congestive heart failure.
*Adjusted for age tertile, CHF, presence of 3-vessel disease, left ventricular ejection fraction, and renal disease (end-stage renal disease and chronic renal insufficiency).












 HADS-ANX Quartile 1
 HADS-ANX Quartile 2
 HADS-ANX Quartile 3
 HADS-ANX Quartile 4
Figure 2. Hazard plot of the association between quartile of
Hospital Anxiety and Depression Scale–Anxiety (HADS-A) score and
mortality.
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an explanatory role that may be clinically important in the
identification of patients at higher risk of mortality. The
increased mortality risk was most pronounced in the patient
group with comorbid anxiety and depression, in whom the risk
of mortality was 3-fold higher than in patients with neither
anxiety nor depression.
Association of Anxiety With All-Cause Mortality
The current findings that elevated anxiety symptoms were
associated with a 2-fold increased risk of mortality in CHD
patients are consistent with previous reports of an approximate
2-fold increased risk of mortality associated with anxiety in
hospitalized patients undergoing CABG21,24 and in cardiac
patients tested outside the hospital environment.20,23,25 For
example, Frasure-Smith and colleagues23 reported that CHD
patients with generalized anxiety disorder (GAD) assessed
2 months following hospital discharge for acute coronary
syndrome showed a 2.3-fold increased risk of adverse cardiac
events, and Strik et al25 reported a 2.8-fold increased risk of
adverse events in acute post-MI patients in whom anxiety was
measured 1 month following hospital discharge. Similarly, a
2-fold increased risk of adverse eventswas also found in cardiac
patients with stable coronary disease undergoing rehabilita-
tion20 and in patients with consistently elevated anxiety during
annual clinic visits.26 However, anxiety has not been found to be
related to mortality risk in cardiac patients evaluated during
hospitalization for an acute myocardial infarction.28–31 In
addition, in a sample of 4864 patients undergoing exercise
stress testing, elevated anxiety was predictive of increased risk
of mortality only in those patients with left ventricular
dysfunction. In the remaining patients, anxiety assessed at
the time of stress testing was found to be associated with
improved survival.43 These findings suggest that anxiety may
convey some protective effects, possibility through increased
motivation to seek and comply with health-promoting behavior,
despite its association with overall health-damaging conse-
quences in patient populations.
Methodological differences in anxiety assessment may
have contributed to the apparent discrepant findings between
studies. For example, in hospitalized patients following a
major event such as MI, estimation of steady-state levels of
anxiety was made difficult by the substantial fluctuation of
anxiety during hospitalization following MI.44,45 Furthermore,
anxiety is often measured using self-report questionnaires
that are not designed to be used in elderly hospitalized
patients. In addition to failing to differentiate anxiety from
symptoms related to physical disorders, such as dizziness,
insomnia, and fatigue, some of the commonly used question-
naires may be inferior to other anxiety measures in terms of
discriminant and factorial validity46,47 and may be especially
problematic when used to differentiate elderly patients with
diagnosed anxiety disorder from nonanxious patients.47,48
Anxiety and Mortality in the Context of Comorbid
Depression
The present findings that more than half the patients with
elevated HADS-A scores consistent with clinically significant
anxiety (HADS-A≥8) also met criteria for clinical depression
defined as HADS-D score ≥8 are consistent with similar
estimates of high comorbidity between GAD and unipolar
depression.49,50 For example, 58% of the respondents in
the National Comorbidity Survey and 70% of respondents in
the Midlife Development in the United States Survey with
generalized anxiety disorder in the previous 12 months also
met criteria for major depression. Similarly, approximately
two-thirds of patients with panic disorder or agoraphobia
fulfilled criteria for lifetime major depression.51
Patients with comorbid anxiety and depression have been
reported to show a more chronic course of psychopathology,
with significantly greater functional impairment and more
resistance to psychiatric treatment than patients with either
condition alone.49,52–54 Findings from recent twin studies
suggest that a genetic predisposition toward a negative
appraisal of life events may be present in both anxiety and
depression. The presence of this genetic predisposition may
lead to amplification of the perceived stressfulness of major life
events. The present findings of an additive association between
anxiety and depression in relation to mortality risk are
consistent with greater chronicity of anxiety and depression












 HADS-DEP Quartile 1
 HADS-DEP Quartile 2
 HADS-DEP Quartile 3
 HADS-DEP Quartile 4
Figure 3. Hazard plot of the association between quartile of
Hospital Anxiety and Depression Scale–Depression (HADS-D) score
and mortality.
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and suggest that future research should evaluate the efficacy of
stressmanagement or cognitive behavior therapy in this patient
population.
Despite the extensive comorbidity between anxiety and
depression, few studies have accounted for the impact of the
alternate psychosocial factor when evaluating the prognostic
significance of anxiety or depression in CHD patients. The
findings of an approximately 3-fold increased risk of mortality in
patients with comorbid anxiety and depression are consistent
with previous findings of a combined action between anxiety
and depression in the Vietnam Experience Study, in which
veterans with comorbid major depressive disorder (MDD) and
GAD were at substantially greater risk of mortality than the
veterans who reported onlyMDD or GAD.55 Similar evidence for
a combined action between anxiety and depression was
reported in the Olmstead County study, in which the presence
of anxiety and depression conferred greater risk of rehospital-
ization than either factor alone56and in the PROMOTION study,
a randomized clinical trial designed to evaluate the efficacy of
an education intervention in decreasing patient delay in seeking
treatment for CHD symptoms. Patients enrolled in PROMOTION
with depression or anxiety alone were not at greater risk of
mortality; however, those with persistent comorbid symptoms
had significantly higher mortality.57 In addition, 1 previous
study evaluating the impact of anxiety and depression reported
that combining the number of psychosocial risk factors (ie,
anxiety, depression, or depression history) resulted in a
cumulative relationship for a composite-outcome end point
defined by rehospitalization, MI, and cardiac mortality in 222
acute post-MI patients.22 In contrast, a combined effect of
anxiety and depression was not found in a study of 804 CHD
patients, in which the association between generalized anxiety
disorder (GAD) and clinical depression on a composite index of
risk was evaluated.23 Although reduced power may explain the
lack of a combined effect of anxiety and depression in this
study, because only 11 patients were diagnosed with both GAD
and depression in this study, there was also no apparent
combined effect when anxiety and depressive symptoms were
measured using the HADS anxiety scale to assess anxiety and
the Beck Depression Inventory to measure depression.
Study Limitations
Caution must be taken in generalizing the current findings to
all CHD patients for a number of reasons. First, patients who
undergo diagnostic tests such as cardiac catheterization to
explain physical symptoms may be more likely to include
individuals with elevated anxiety and depression.58 Second,
the circumstances associated with the hospitalization or
catheterization procedure may have influenced the assess-
ment of anxiety or depression in some individuals. In
addition, although the HADS was developed specifically to
classify cases of anxiety and depression in a medical setting,
it may offer some disadvantages to the use of a diagnostic
interview to define clinically significant anxiety and depres-
sion. Evaluation of the association between psychosocial
factors and risk of mortality may also have been compro-
mised in this sample by the higher number of deaths
occurring as a direct consequence of a medical procedure.
Exclusion of the procedural deaths, however, did not alter
the strength of the association between elevated anxiety or
elevated depression and mortality risk when these factors
were evaluated separately. When evaluated together, the
association between anxiety and mortality was maintained
(HR, 2.07; 95% CI, 1.30 to 3.30; P=0.002), but depression
had an attenuated association with increased risk of
mortality when the analysis was limited to nonprocedural
deaths (HR, 1.50; 95% CI, 0.93 to 2.44; P=0.10). The findings
were also limited in that substance abuse was not consid-
ered a potential confounding variable. A number of studies
have found high rates of substance use and abuse in
clinically depressed patients and in some types of anxiety
disorders such as posttraumatic stress disorder.59–61 How-
ever, we did examine smoking and alcohol use in the current
cohort and observed an association between current smok-
ing and depressive symptoms. In contrast, anxiety was
unrelated to smoking and was related to significantly lower
alcohol use. It therefore seems plausible that substance
abuse would not explain the association between anxiety and
mortality in the current cohort but could have contributed
to the excess mortality observed in the patients with
depression.
Conclusions
Anxiety and depression are common in CHD patients during
hospitalization for coronary angiography, and each was
independently associated with an approximate 2-fold
increased risk of all-cause mortality. The association of these
factors was additive, with a 3-fold increased risk in anxious
patients with comorbid depression. These findings suggest
that clinicians assess patients for both anxiety and depression
and continue to monitor these symptoms on a regular basis.
Patients with elevated anxiety, particularly when found in the
context of comorbid depression, may benefit from treatment
of anxiety and from more intensive monitoring.
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